Eli Lilly
NMPA Approves Eli Lilly, Innovent's Immunotherapy Tyvyt for EGFR-Mutant NSCLC
The approval marks the first PD-1 inhibitor to be approved for patients with EGFR-mutant NSCLC.
Early studies of KRAS inhibitors from Loxo Oncology, Genentech, and Innovent suggest newer drugs have activity in KRAS G12C-resistant patients.
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
FDA Expands Early-Stage Breast Cancer Indication for Eli Lilly's Verzenio in Adjuvant Setting
The drug can now be given with endocrine therapy to patients with HR-positive HER2-negative breast cancer that's node-positive and at high risk of recurrence.
GenFleet Therapeutics Cleared in Europe to Study KRAS, EGFR Inhibitor Combo in NSCLC Patients
The trial will evaluate GenFleet's GFH925 with Eli Lilly's Erbitux (cetuximab) as a first-line treatment for non-small cell lung cancer patients with KRAS G12C mutations.
Sep 13, 2022